Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii

Zhanel, 2019, Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli, Drugs, 79, 271, 10.1007/s40265-019-1055-2 Dobias, 2017, Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens, Eur J Clin Microbiol Infect Dis, 36, 2319, 10.1007/s10096-017-3063-z Kohira, 2016, In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae Clinical isolates, including carbapenem-resistant strains, Antimicrob Agents Chemother, 60, 729, 10.1128/AAC.01695-15 Ito, 2016, In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria, J Antimicrob Chemother, 71, 670, 10.1093/jac/dkv402 Shionogi Inc, 2019 Zingg, 2020, Cefiderocol for extensively-drug resistant gram-negative bacterial infections: real-world experience from a case-series and review of the literature, Open Forum Infect Dis, 7, ofaa185, 10.1093/ofid/ofaa185 Trecarichi, 2019, Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report, J Antimicrob Chemother, 74, 3399, 10.1093/jac/dkz318 Dagher, 2020, Case report: successful rescue therapy of extensively drug resistant Acinetobacter baumannii osteomyelitis with cefiderocol, Open Forum Infect Dis, 7, ofaa150, 10.1093/ofid/ofaa150 Stratton, 1988, Serum bactericidal test, Clin Microbiol Rev, 1, 19, 10.1128/CMR.1.1.19 CLSI, 1999 Cui, 2019, Tigecycline-induced coagulopathy: a literature review, Int J Clin Pharm, 41, 1408, 10.1007/s11096-019-00912-5 Isler, 2019, New treatment options against carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 63, 10.1128/AAC.01110-18 Du, 2019, Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis, Am J Infect Control, 47, 1140, 10.1016/j.ajic.2019.03.003 Yamano, 2019, In vitro activity of cefiderocol against a broad range of clinically important gram-negative Bacteria, Clin Infect Dis, 69, 10.1093/cid/ciz827 Edgeworth, 2019, Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to extremely drug-resistant Pseudomonas aeruginosa, Clin Infect Dis, 68, 1932, 10.1093/cid/ciy963 Stevens, 2019, Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug-resistant Pseudomonas aeruginosa: a case report, Pharmacotherapy, 39, 1113, 10.1002/phar.2334 Portsmouth, 2018, Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial, Lancet Infect Dis, 18, 1319, 10.1016/S1473-3099(18)30554-1 Saisho, 2018, Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative Bacteria, in healthy subjects, Antimicrob Agents Chemother, 62, e02163, 10.1128/AAC.02163-17 Alamarat, 2020, Long term compassionate use of cefiderocol to treat chronic osteomyelitis caused by XDR-Pseudomonas aeruginosa and ESBL-producing Klebsiella pneumoniae in a pediatric patient, Antimicrob Agents Chemother, 64, e01872, 10.1128/AAC.01872-19 Spaziante, 2019, Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report, Open Forum Infect Dis, 6, ofz427, 10.1093/ofid/ofz427 Zaghi, 2020, Serum bactericidal titres for monitoring antimicrobial therapy: current status and potential role in the management of multidrug-resistant gram-negative infections, Clin Microbiol Infect, 26, 1338, 10.1016/j.cmi.2020.04.036 Roberts, 2014, Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions, Lancet Infect Dis, 14, 498, 10.1016/S1473-3099(14)70036-2